| UHC UMR Medical and Drug | Scenesse® (Afamelanotide) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Tocilizumab Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Adzynma (ADAMTS13, Recombinant-Krhn) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Korsuva® (Difelikefalin) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Saphnelo® (Anifrolumab-Fnia) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Scenesse® (Afamelanotide) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Tocilizumab Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| Humana Medicaid | Ambulatory Withdrawal Management - MEDICAID - OHIO | 2026-07-01 |
| Humana Medicare Advantage | Breast Imaging - Medicare Advantage | 2026-07-01 |
| Humana Medicaid | Community Behavioral Health Rehabilitative Services - MEDICAID - OHIO | 2026-07-01 |